Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

“Critical” Drug List Would Be Created Under Shortages Bill

This article was originally published in The Pink Sheet Daily

Executive Summary

Draft bill being developed by Rep. John Carney, D-Del., also would create system to notify the public and other manufacturers of pending shortages.

You may also be interested in...



Shortage Notification May Have Legislative Momentum Again After BIO Questions Reimbursement Fix

Preventing shortages through increased communications with manufacturers could gain the upper hand in part because creating economic incentives may prove too difficult and controversial.

“Comprehensive” Drug Shortage Mitigation Bill Under Development In House

Like the Senate proposal, it could include reimbursement rate adjustments in addition to requiring early notification of shortages by manufacturers, but questions remain about ensuring there are no unintended consequences.

FDA’s Drug Shortage Prevention Tally: 96 Saves In Six Weeks

At Senate hearing, the agency says an executive order has helped spur notifications, while the GAO suggests Congress require manufacturers to tell FDA about anything that could affect the drug supply. Reimbursement changes will not solve the shortage problem, an HHS official argues.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS073292

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel